benznidazole Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antiprotozoals and radiosensitizers, metronidazole derivatives 322 22994-85-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • benznidazole
  • benznidazol
  • benzonidazol
  • benzonidazole
  • radanil
Benznidazole inhibits the synthesis of DNA, RNA, and proteins within the T. cruzi parasite. Studies suggest that benznidazole is reduced by a Type I nitroreductase (NTR) enzyme of T. cruzi producing a series of short-lived intermediates that may promote damage to several macromolecules including DNA. In mammalian cells, however, benznidazole is metabolized by reduction of the nitro group to an amino group by a Type II NTR enzyme. The precise mechanism of action is not known. Benznidazole is active against all three stages, trypomastigotes, amastigotes, and epimastigotes, of T. cruzi. However, the sensitivity of T. cruzi strains to benznidazole, from different geographic regions, may vary.
  • Molecular weight: 260.25
  • Formula: C12H12N4O3
  • CLOGP: 0.90
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 90.06
  • ALOGS: -2.83
  • ROTB: 5

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.40 mg/mL Benet LZ, Broccatelli F, Oprea TI

Approvals:

DateAgencyCompanyOrphan
Aug. 29, 2017 FDA CHEMO RESEARCH SL

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cross sensitivity reaction 35.82 24.91 4 3 2083 53346976

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
American trypanosomiasis 51.02 42.62 5 7 231 32513283

Pharmacologic Action:

SourceCodeDescription
ATC P01CA02 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ANTIPROTOZOALS
AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS
Nitroimidazole derivatives
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000977 Antiparasitic Agents
MeSH PA D000981 Antiprotozoal Agents
MeSH PA D007155 Immunologic Factors
MeSH PA D007166 Immunosuppressive Agents
MeSH PA D009153 Mutagens
MeSH PA D009676 Noxae
MeSH PA D014344 Trypanocidal Agents
CHEBI has role CHEBI:35820 antiprotozoal agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Infection by Trypanosoma cruzi indication 77506005

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.65 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
100MG BENZNIDAZOLE CHEMO RESEARCH SL N209570 Aug. 29, 2017 RX TABLET ORAL Aug. 29, 2022 NEW CHEMICAL ENTITY
12.5MG BENZNIDAZOLE CHEMO RESEARCH SL N209570 Aug. 29, 2017 RX TABLET ORAL Aug. 29, 2022 NEW CHEMICAL ENTITY
100MG BENZNIDAZOLE CHEMO RESEARCH SL N209570 Aug. 29, 2017 RX TABLET ORAL Aug. 29, 2024 FOR USE IN CHILDREN AGES 2 TO 12 YEARS OLD WITH CHAGAS DISEASE
12.5MG BENZNIDAZOLE CHEMO RESEARCH SL N209570 Aug. 29, 2017 RX TABLET ORAL Aug. 29, 2024 FOR USE IN CHILDREN AGES 2 TO 12 YEARS OLD WITH CHAGAS DISEASE

Bioactivity Summary:

None

External reference:

IDSource
D02489 KEGG_DRUG
18994 RXNORM
C0053230 UMLSCUI
CHEBI:133833 CHEBI
CHEMBL110 ChEMBL_ID
DB11989 DRUGBANK_ID
31593 PUBCHEM_CID
C009999 MESH_SUPPLEMENTAL_RECORD_UI
3541 INN_ID
YC42NRJ1ZD UNII
261813 MMSL
27035 MMSL
d07580 MMSL
008175 NDDF
714091003 SNOMEDCT_US
714092005 SNOMEDCT_US
4037055 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Benznidazole HUMAN PRESCRIPTION DRUG LABEL 1 0642-7463 TABLET 12.50 mg ORAL NDA 31 sections
Benznidazole HUMAN PRESCRIPTION DRUG LABEL 1 0642-7464 TABLET 100 mg ORAL NDA 31 sections